- Home
- IDR vs PRTC Comparison
IDR vs PRTC Comparison
Compare IDR & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- PRTC
- Stock Information
- Founded
- IDR 1996
- PRTC 2015
- Country
- IDR United States
- PRTC United States
- Employees
- IDR N/A
- PRTC N/A
- Industry
- IDR Precious Metals
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- IDR Basic Materials
- PRTC Health Care
- Exchange
- IDR Nasdaq
- PRTC Nasdaq
- Market Cap
- IDR 378.0M
- PRTC 413.5M
- IPO Year
- IDR N/A
- PRTC N/A
- Fundamental
- Price
- IDR $25.51
- PRTC $18.01
- Analyst Decision
- IDR Strong Buy
- PRTC Buy
- Analyst Count
- IDR 1
- PRTC 1
- Target Price
- IDR $17.50
- PRTC $45.00
- AVG Volume (30 Days)
- IDR 475.0K
- PRTC 2.8K
- Earning Date
- IDR 08-07-2025
- PRTC 08-27-2025
- Dividend Yield
- IDR N/A
- PRTC N/A
- EPS Growth
- IDR 57.55
- PRTC N/A
- EPS
- IDR 0.64
- PRTC 0.21
- Revenue
- IDR $30,496,328.00
- PRTC $4,828,000.00
- Revenue This Year
- IDR $21.91
- PRTC N/A
- Revenue Next Year
- IDR $5.47
- PRTC N/A
- P/E Ratio
- IDR $39.96
- PRTC $8.19
- Revenue Growth
- IDR 59.64
- PRTC 44.98
- 52 Week Low
- IDR $9.58
- PRTC $13.30
- 52 Week High
- IDR $27.39
- PRTC $25.00
- Technical
- Relative Strength Index (RSI)
- IDR 71.70
- PRTC 49.08
- Support Level
- IDR $23.11
- PRTC $15.21
- Resistance Level
- IDR $27.39
- PRTC $18.20
- Average True Range (ATR)
- IDR 1.54
- PRTC 0.54
- MACD
- IDR 0.56
- PRTC -0.12
- Stochastic Oscillator
- IDR 83.41
- PRTC 71.92
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.